[Leishmania epidemiology, diagnosis, chemotherapy and vaccination approaches in the international network of Pasteur Institutes]

Med Sci (Paris). 2013 Dec;29(12):1151-60. doi: 10.1051/medsci/20132912020. Epub 2013 Dec 20.
[Article in French]

Abstract

Protozoan parasites of the genus Leishmania generate severe human diseases termed leishmaniases. Due to their frequency and the severity of certain clinical forms, these diseases represent a major public health problem and limit the economic growth in various developing countries. The presence of Pasteur Institutes in countries with endemic leishmaniasis has provided important incentives to develop a strong public health agenda in the Pasteur scientific community with respect to this important disease. A concerted effort is now coordinated through the recently created LeishRIIP platform (www.leishriip.org), which aims to identify synergies and complementary expertise between the eleven members of the international network of Pasteur Institutes working on various aspects of the disease including epidemiology, diagnosis, chemotherapy and vaccination.

Publication types

  • English Abstract

MeSH terms

  • Academies and Institutes
  • Animals
  • Antiprotozoal Agents / adverse effects
  • Antiprotozoal Agents / therapeutic use*
  • Developing Countries
  • Disease Vectors
  • Endemic Diseases
  • Humans
  • International Cooperation
  • Leishmania* / immunology
  • Leishmaniasis* / drug therapy
  • Leishmaniasis* / epidemiology
  • Leishmaniasis* / prevention & control
  • Public Health
  • Vaccination*

Substances

  • Antiprotozoal Agents